Skip to main content

Eli Lilly and Company Value Stock - Dividend - Research Selection


ISIN: US5324571083 , WKN: 858560

Market price date:
Market price:  

Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Key figures
Cash flow
Balance sheet
Income statement
Div. Yield%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization USD
Raw Data Source
Stock Split

Description of the company

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions. The company also provides neuroscience products for the treatment of depressive disorder, diabetic peripheral neuropathic pain, anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorder; obsessive-compulsive disorder, bulimia nervosa, and panic disorder; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains, as well as immunology products to treat Alzheimer\'s disease. In addition, it offers oncology products to treat non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products to treat erectile dysfunction and benign prostatic hyperplasia; and migraine. Further, the company provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine and cattle; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry use; and chewable tablets that kill fleas and prevent heartworm diseases. Additionally, it offers vaccines to prevent bordetella, Lyme disease, rabies, and parvovirus. The company has collaboration agreements with Daiichi Sankyo Co., Ltd.; Incyte Corporation; Pfizer Inc.; AstraZeneca; and Nektar Therapeutics, as well as has strategic collaboration with Sigilon Therapeutics. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,


Eli Lilly: Best-Now Near-Term Price Gains Pharmaceuticals Stock

84% of Eli Lilly's shares are held by 3370 institutional investors. See why LLY is the best near-term pharma stock to Buy now.

Eli Lilly & Co. stock outperforms market despite losses on the day

Shares of Eli Lilly & Co. sank 0.03% to $330.97 Wednesday, on what proved to be an all-around grim trading session for the stock market, with the S&P 500...

Roche Joins Hand With Lilly To Improve Early Diagnosis Of Alzheimer's Disease

Roche (OTC: RHHBY) announces collaboration with Eli Lilly and Company (NYSE: LLY) to support the development of its Elecsys Amyloid Plasma Panel (EAPP). The EAPP is a blood test that aims to facilitate the earlier diagnosis of Alzheimer’s disease. If approved, the EAPP test would be an additional tool to identify low likelihood of amyloid pathology in symptomatic patients and determine whether they should proceed to further evaluation and testing that may confirm a diagnosis. Also Read: New Four

Eli Lilly Is Priced for Perfection in the Obesity Market

The company has outperformed its pharma peers in recent years, but its valuation leaves little room for error.

Stifel argues sympathy trading not a predictor for Viking`s pending VK2735 data

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Roche to collaborate with Lilly on early diagnosis of Alzheimer`s disease

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Wall Street Breakfast Podcast: Federal Reserve: Hike Or Not

Federal Reserve faces dilemma — to hike or not as financial shock complicates. GameStop soars 31% after the retailer records a surprise Q4 profit. Credit Suisse staff deferred bonuses.

Roche teams up with Lilly to validate Alzheimer's blood test

Roche and Eli Lilly and Co are joining forces to develop a blood test for Alzheimer's disease, and plan to kick off a two-year clinical trial involving hundreds of volunteers with the aim of winning U.S. regulatory approval. The effort, unveiled in a statement on Wednesday, comes as Lilly as well as Eisai and Biogen are gearing up to sell drugs aimed at slowing the advance of the mind-robbing illness, but their use will require a diagnosis at earlier disease stages than is the norm today. Roche Holding AG would recruit several hundred volunteers with early signs of dementia over the next 18 to 24 months with trial data potentially ready for a U.S. regulatory filing in 2025, Bruce Jordan, leader of Personalized Healthcare Solutions at Roche Diagnostics, told Reuters.

Roche and Eli Lilly collaborate on blood test for Alzheimer's disease

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.

Lilly, Roche team up to develop blood test for Alzheimer`s disease

Looking for stock market analysis and research with proves results? offers in-depth financial research with over 30years of proven results.